Compare MobilEye Global Inc (MBLY) vs TG Therapeutics Inc (TGTX) Price & Performance

Mobileye Global (MBLY) trades at $7.10, down 0.7% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with strong revenue growth to $2.0B in 2026 but deep net losses widening to -$4.1B. Analyst consensus leans bullish with 57.7% buy ratings and $10.83 price target, though technical indicators show selling pressure with RSI near oversold levels at 29.04. Recent news highlights ADAS business momentum and autonomous vehicle expansion initiatives.

MBLY presents a high-risk opportunity with significant upside potential if execution improves, but current profitability challenges and bearish technicals warrant caution. The 42% discount to book value and institutional accumulation offer value appeal, though sustained losses and competitive pressures in autonomous driving create substantial execution risk for investors.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.